Nancy Ryan Gray sold $1.4M of LGND
director at LIGAND PHARMACEUTICALS INC. 6,571 shares at an average of $205.45, traded Nov 7, 2025, filed Nov 12, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.4M at market
- +20Share of holdings soldSold 56% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002001011-25-000098, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2025 | MOption exercise Common Stock | +3,556 | $66.19 | $235k | 11,650 | Nov 12, 2025 |
| Nov 7, 2025 | SOpen-market sale Common Stock | -3,556 | $205.45 | $731k | 8,094 | Nov 12, 2025 |
| Nov 7, 2025 | MOption exercise Common Stock | +3,015 | $73.57 | $222k | 11,109 | Nov 12, 2025 |
| Nov 7, 2025 | SOpen-market sale Common Stock | -3,015 | $205.45 | $619k | 8,094 | Nov 12, 2025 |
| Nov 7, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -3,556 | $0.00 | $0 | 0 | Nov 12, 2025 |
| Nov 7, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative | -3,015 | $0.00 | $0 | 0 | Nov 12, 2025 |
Related signals
Other insiders at LIGAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.5M 5,000 shares | -14% | |
| 43Moderate | LIGAND PHARMACEUTICALS INC | Martine Zimmermann director | $342k 1,200 shares | -24% | |
| 33Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.4M 5,000 shares | -12% | |
| 45Moderate | LIGAND PHARMACEUTICALS INC | Octavio Espinoza Chief Financial Officer | $340k 1,804 shares | -6% | |
| 12Weak | LIGAND PHARMACEUTICALS INC | John W Kozarich director | $91k 467 shares | -1% | |
| 43Moderate | LIGAND PHARMACEUTICALS INC | John L Lamattina director | $859k 4,179 shares | -13% | |
| 19Weak | LIGAND PHARMACEUTICALS INC | John W Kozarich director | $89k 467 shares | -1% | |
| 12Weak | LIGAND PHARMACEUTICALS INC | John W Kozarich director | $84k 467 shares | -1% | |
| 53Moderate | LIGAND PHARMACEUTICALS INC | Jason Aryeh director | $1.7M 10,000 shares | -13% | |
| 3Weak | LIGAND PHARMACEUTICALS INC | John W Kozarich director | $76k 467 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.